Here, we demonstrated that, in principle, RAC1-amp and RAC1-A159V-mutated HNSCC were pharmacologically vulnerable to Rac inhibitor targeting with EHop-016 in vivo (in both PDXs and xenografts), with no apparent toxicity. The gene discussed is RAC1; the disease is head and neck squamous cell carcinoma.